DALLAS, Dec. 2, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Somaxon Pharmaceuticals Inc. (Nasdaq:SOMX). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Somaxon Pharmaceuticals Inc. (Nasdaq:SOMX) should be of particular interest to other drug manufacturers: GlaxoSmithKline Plc, Pfizer Inc. and Sanovi-Aventis.
It is available at: http://www.investorsoup.com/lp/SOMX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Somaxon Pharmaceuticals Inc. (SOMX) is a specialty pharmaceutical company focused on the in-licensing and development of product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. The Company is focused on the development of Silenor. SOMX completed its new drug application (NDA) for Silenor and submitted it to the United States Food and Drug Administration (FDA) on January 31, 2008.
Message Board Search for SOMX: http://www.boardcentral.com/boards/SOMX
In the report, the analyst notes:
"In a clinical trial to evaluate Silenor 3 mg and 6 mg in the treatment of adults (n=229) with chronic insomnia in a sleep laboratory setting, Silenor demonstrated a statistically significant improvement compared to placebo for both doses on the primary endpoint of wake after sleep onset (WASO) as well as a range of secondary endpoints including latency to persistent sleep (LPS) total sleep time (TST) sleep efficiency (SE), subjective Wake After Sleep Onset (sWASO), and subjective Total Sleep Time (sTST) in each case at night one.
"For the third quarter of 2009, net loss applicable to common stockholders was $1.8 million, or $0.08 per share, compared with $10.3 million, or $0.56 per share, for the third quarter of 2008. As a development stage pharmaceutical company, SOMX had no revenues during the third quarter of 2009."
To read the entire report visit: http://www.investorsoup.com/lp/SOMX
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.